Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025)
Apollomics' (APLM) quarterly Total Non-Current Liabilities came in at $3.6 million in Q4 2025, up 328.26% year-over-year from $835000.0 in Q4 2024, and down 29.12% quarter-over-quarter from $5.0 million in Q2 2025.
Analysis
Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Total Non-Current Liabilities for 5 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 328.26% year-over-year to $3.6 million in Q4 2025; TTM through Dec 2025 was $3.6 million, a 328.26% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, up 328.26% from the prior year.
- Total Non-Current Liabilities was $3.6 million for Q4 2025 at Apollomics, down from $5.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $512.2 million in Q4 2022 and troughed at -$212.9 million in Q4 2021.
- A 5-year average of $39.0 million and a median of $1.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 99.88% in 2023 and surged 351.66% in 2025, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at -$212.9 million in 2021, then soared by 340.64% to $512.2 million in 2022, then sank by 99.88% to $597000.0 in 2023, then jumped by 39.87% to $835000.0 in 2024, then surged by 328.26% to $3.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $3.6 million (Q4 2025), $5.0 million (Q2 2025), and $835000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | 3.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 3.58 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Dec 31, 2024 | 835,000.00 |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 597,000.00 |
| Jun 30, 2023 | 1.55 Mn |
| Dec 31, 2022 | 512.24 Mn |
| Dec 31, 2021 | -212.86 Mn |